Abstract: A pharmaceutical composition comprising 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl-4H-pyrano[3,2-g]quinoline-2,8-dica rboxylic acid or a pharmaceutically acceptable salt thereof, a pressurized or liquefied gas propellant, and a flavoring agent and/or a sweetening agent is useful in the treatment of reversible obstructive airways disease. The composition preferably contains nedocromil sodium as active ingredient. Flavoring agents which may be used include menthol and peppermint oil. Sweetening agents which may be used include sugar, aspartame, cyclamates and saccharin or salts thereof. The composition preferably includes both a flavoring agent and a sweetening agent. Any conventional aerosol propellant may be used, e.g. a mixture of Propellant 12 and Propellant 114, and the composition is preferably packaged in a conventional pressurized aerosol canister fitted with a dispensing metering valve.

Abstract: A disposable device for the administration of powdered inhalation medicament is provided which comprises a rigid medicament reservoir (4) holding a unit dose of medicament (10) and having air inlet means (5,7) and medicament outlet means (8); and closure means (3) which are removable in use; wherein the medicament (10) held in the reservoir (4) is in loose powder form.

Abstract: An improved apparatus and method for plasma source mass spectrometry, the apparatus comprising: means (16) for generating a plasma (15) at substantially atmospheric pressure in a gas; means (4) for introducing a sample to the plasma wherein the sample is ionized to form sample ions (17); means (19, 23) for transmitting the ions from the plasma into an evacuated chamber (24); a mass filter (26) disposed within the evacuated chamber; a substantially non-multiplying ion detector (58) comprising an ion collector (59), the detector being responsive to the charge of at least some of the sample ions which pass through the mass filter; and means for inhibiting the response of the detector to electrically neutral particles. Typically the detector comprises a suppressor (63) and means (64) for negatively biassing the suppressor with respect to the collector, and also a shield (61) disposed to shield the suppressor from the neutral particles.

Abstract: Compounds of formula I, ##STR1## wherein R.sup.1 represents H, OH, protected OH or alkoxy; R.sup.2 represents H; R.sup.3 represents O or (H,OH); R.sup.4 represents methyl, ethyl, propyl or allyl; R.sup.5 represents OH, protected OH or alkoxy; R.sup.6 represents OH; R.sup.7 represents OH, alkoxy or NR.sup.8 R.sup.9 where R.sup.8 and R.sup.9 independently represent H, alkyl or aryl; in addition, R.sup.1 and R.sup.2 may together represent a second bond between the carbon atoms to which they are attached; and R.sup.6 and R.sup.7 may together represent O; and pharmaceutically acceptable salts thereof; are useful inter alia as immunosuppressive agents. The invention also provides the novel compounds of formula I.

Abstract: Pharmaceutical compositions suitable for administration by inhalation and containing pentamidine, or pharmaceutically acceptable salt thereof, in powder form. Such compositions include pressurized aerosol compositions and non-pressurized powder compositions. Also described is finely divided powdered pentamidine with a mass median diameter in the range 0.01 to 10 microns and a method for the prevention or treatment of pneumacystics carinii pneumonia which comprises administration by inhalation to a patient having or susceptible to that condition of a therapeutically effective quantity of pentamidine, or a pharmaceutically acceptable salt thereof, in powder form.

Abstract: Particulate nedocromil sodium with a mass median diameter of from 5 to 10 .mu.m is useful as a medicament for inhalation.The particulate nedocromil sodium of the invention is particularly advantageous in that its dispersion, i.e. the proportion of particles which are capable of penetrating deep into the lung, is substantially greater than the dispersion of conventional powders having smaller mass median diameters.

Abstract: There are described compounds of formula I, ##STR1## wherein R.sup.1 represents H or OH; R.sup.2 represents H; in addition, R.sup.1 and R.sup.2 may together represent a second carbon-carbon bond between the carbon atoms to which they are attached; R.sup.3 represents OH or OCH.sub.3 ; X represents O or (H,OH); and Y represents O or N--OR.sup.4, in which R.sup.4 represents H or alkyl C.sub.1-6 ; provided that when R.sup.1 is OH, R.sup.2 is H and X is O, then Y does not represent O.Processes for their production and compositions containing them, eg. for use as immunosuppressive agents, are also described.

Abstract: A device for the administration by inhalation of a medicament in powdered form. The device includes a supply of the medicament in the form of a compacted body of powered medicament, a rotatable helical blade which abrades a desired quantity of the medicament from the compacted body, and a mouthpiece through which the abraded powder can be inhaled by the user of the device.

Abstract: A mass spectrometer comprising ion source means (1) for producing ions characteristic of a sample to be analysed; ion detector means (14) for receiving at least some of said ions; magnetic sector analyzing means (18) and electrostatic analyzing means (8) disposed in any order between said ion source means (1) and said ion detector means (14); wherein said magnetic sector analyzing means (18) comprises means for dispersing ions according to their mass-to-charge ratios and for transmitting ions whose mass-to-charge ratios lie within a predetermined range and have a first kinetic energy; said electrostatic analyzing means (8) comprises means for generating an electrostatic field for deflecting ions having different kinetic energies around different curved trajectories such that ions having a second kinetic energy, lower than said first kinetic energy, are deflected around a central curved trajectory (15) and transmitted through said electrostatic analyzing means (8), and the strength of said electrostatic field

Abstract: Phenylethylamine derivatives of the formula ##STR1## wherein D.sub.1 represents a phenylethyl radical which is substituted with hydroxy and/or alkyl groups,R.sub.1 and R.sub.2 are hydrogen or alkyl,D.sub.2 represents hydrogen, an alkyl, or aryl group, and n is an integer from 3 to 5.These compounds are useful as pharmaceuticals, e.g., for treatment of cardiovascular conditions.

Abstract: There are described compounds of formula I, ##STR1## in which Ar.sub.1 and Ar.sub.2, which may be the same or different, each independently represent phenyl or pyridinyl, the phenyl or the pyridinyl each optionally being substituted by one or more of halogen; hydroxy; --COOR.sub.12 ; trihalomethyl; alkoxy C1 to 6; alkyl C1 to 6; --NR.sub.1 R.sub.2 ; alkoxy C1 to 6 substituted by --NR.sub.1 R.sub.2 or by phenyl; or alkyl C1 to 6 substituted by --NR.sub.1 R.sub.2 or by --COOR.sub.12 ;R.sub.1 and R.sub.2, which may be the same or different, each independently represent hydrogen or alkyl C1 to 6,R.sub.3 represents hydrogen, alkyl C1 to 6, alkanoyl C1 to 6, benzoyl, --COOR.sub.8, or --CONHR.sub.11,R.sub.4, R.sub.5, R.sub.6 and R.sub.7, which may be the same or different each independently represent hydrogen, alkyl C1 to 6 or phenyl;R.sub.8 represents alkyl C1 to 6 or aryl,R.sub.11 represents alkyl C1 to 6 or aryl,R.sub.12 represents hydrogen or alkyl C1 to 6, and pharmaceutically acceptable derivatives thereof.

Abstract: Compounds of the formula, ##STR1## in which one of R.sub.30 and R.sub.40 represents a substituted phenylalkyl group and the other of R.sub.30 and R.sub.40 represents hydrogen or halogen, and R.sub.50 and R.sub.60 each independently represent hydrogen or alkyl.The compounds of the invention are useful for the treatment or prophylaxis of renal failure or cardiovascular disease.

Abstract: There is described a pharmaceutical composition comprising nedocromil sodium and liposomes.There is also described an aqueous suspension comprising nedocromil sodium partitioned between a free aqueous phase and a liposome phase.There ae also described a method of making the compositions and their use in the manufacture of a medicament for the treatment of reversible obstructive airways disease.

Abstract: There are described compounds of formula I, ##STR1## in which Y is S, O or NR.sub.9,n is 0 or 1,R.sub.9 is hydrogen or alkyl C 1 to 10,R.sub.3 is hydrogen, alkyl C 1 to 10, cycloalkyl C3 to 10, CF.sub.3, SR.sub.10, a 5 or 6 membered heterocyclic group containing one or more S, O or N atoms, NR.sub.4 R.sub.5, phenyl or phenylalkyl C7 to 12, the phenyl, phenylalkyl and heterocyclic groups optionally being fused to a further phenyl group, the heterocyclic group and any phenyl group optionally being substituted by alkyl C 1 to 6, halogen, alkoxy C 1 to 6, nitro, nitrile, CF.sub.3, SR.sub.6, NR.sub.7 R.sub.11 or hydroxy,R.sub.6, R.sub.7 and R.sub.11, which may be the same or different, are each hydrogen or alkyl C 1 to 10,R.sub.4 and R.sub.5, which may be the same or different, are each hydrogen, alkyl C 1 to 10 or phenyl,R.sub.10 is alkyl C 1 to 10,X.sub.1 is S or O, andA is a chain comprising from 2-16 atoms, which chain carries an O or S containing substitutent at a position 2-6 atoms away from the group C=X.

Abstract: Novel compounds of the formula ##STR1## in which one of R.sub.30 and R.sub.40 represents a substituted phenylalkyl group,the other of R.sub.30 and R.sub.40 represents hydrogen or halogen, andR.sub.50 and R.sub.60 each independently represent hydrogen or alkyl; in addition R.sub.60 may represent a substituted alkyl chain interrupted by N.The compounds of the invention are useful for the treatment or prophylaxis of renal failure or cardiovascular disease.

Abstract: There are described new forms of nedocromil sodium, methods of producing these new forms and pharmaceutical formulations, especially pressurized inhalation aerosol formulations, containing finely divided nedocromil sodium. The formulations are indicated for the treatment of reversible obstructive conditions of the airways.

Abstract: There is described a pharmaceutical composition comprising liposomes and sodium cromoglycate. There is also described an aqueous suspension comprising sodium cromoglycate partitioned between a free aqueous phase and a liposome phase. There is further described a method for making the compositions and their use in the treatment of allergic conditions, e.g., asthma.

Abstract: Compounds of formula I, ##STR1## in which A is a 5 or 6 membered, fully unsaturated, carbocyclic or heterocyclic ring,B is a 5 or 6 membered, fully unsaturated, nitrogen containing heterocyclic ring,X is NR.sub.19, O or S,R.sub.19 is hydrogen or alkyl optionally substituted by --OCOR,n is 0 or 1,R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 have various significances,R.sub.1 and R.sub.2, are hydrogen or alkyl or together with the ring carbon atoms to which they are attached, form a benzene or pyridine ring, which ring carries substituents R.sub.15, R.sub.16, R.sub.17 and R.sub.18,R.sub.15, R.sub.16, R.sub.17 and R.sub.18, have varioussignificances, with certain provisos are described.Processes for making the compounds and pharmaceutical formulations containing them, e.g. for the treatment of conditions including excess gastric acid secretion, are also described.

Abstract: There is described a water soluble compound having a molecular weight of from about 70,000 to about 2,000,000 and having the formula I,B--X--(PS)--X--(H) Iin which PS is a polysaccharide of molecular weight from about 2,000 to about 2,000,000,X is a covalently bonded chemical bridging group,H is a group Hb or Hb--ZB is a blocked activating groupHb is a hemoglobin residue, andZ is an oxygen affinity reducing ligand containing two or more phosphate groups.There are also described processes for making the compounds, and their formulations and use as oxygen transporting agents.